Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou's Alphamab Closes $60 Million Series B for Biologic Oncology Portfolio

publication date: May 28, 2019

Alphamab Oncology of Suzhou closed a $60 million Series B led by Hudson Bay Capital Management to support its biologic oncology drug business. Using its experience in protein development, Alphamab is building a portfolio of multi-functional biologic therapies for cancer indications, including bispecific and mix-mAb platforms. The company will use the money for R&D and manufacturing facilities, clinical development of its pipeline and upcoming commercial launch of its lead candidate. In November 2018, Alphamab raised $130 million in a Series A financing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital